Acting CDC Director Jim O’Neill publicly suggested separating the combined measles-mumps-rubella (MMR) vaccine into three single-antigen shots, urging manufacturers via a post on X to produce “safe monovalent vaccines.” That proposal echoed a recent public call from former President Trump. Monovalent measles, mumps or rubella vaccines are not licensed in the United States, and the CDC notes there is no scientific evidence supporting splitting the combined MMR vaccine.
Separately, the CDC’s Advisory Committee on Immunization Practices (ACIP) — reconstituted earlier this year by HHS Secretary Robert F. Kennedy Jr., who appointed several members critical of current vaccine policy — voted in September on several changes to the childhood and COVID-19 vaccine schedules. Observers described the meetings as tense and at times disorganized, and critics said some motions were advanced without new safety data or the customary preparatory analyses.
MMRV and MMR
ACIP voted 8–3 to stop recommending the combined MMRV (measles, mumps, rubella, varicella) vaccine for children under age 4. The panel cited evidence that MMRV carries a modestly higher risk of febrile seizures — roughly double the risk compared with giving MMR and varicella as separate injections — while stressing the absolute risk is low and these seizures are typically not serious. Experts noted the risk profile is long-established, and that only about 15% of parents currently opt for the combined MMRV. Critics argued that removing the recommendation reduces parental choice and will increase the number of injections some children receive without a clear public-health advantage.
Hepatitis B
ACIP debated a proposal to delay the hepatitis B vaccine given at birth but, after heated discussion, tabled the measure indefinitely. No new safety concerns were presented during the debate. Public-health experts cautioned that the newborn dose has been critical in preventing lifelong hepatitis B infection and related liver cancer, and warned that restricting the birth dose risks reversing those public-health gains.
COVID-19 vaccines
The committee narrowed its guidance on COVID-19 vaccination. ACIP now recommends routine COVID-19 vaccination primarily for adults 65 and older. For people ages 6 months through 64, vaccination is not prohibited but is placed under a ‘‘shared clinical decision-making’’ framework, meaning patients and clinicians should weigh individual risks and benefits. A more restrictive proposal that would have required prescriptions for COVID-19 vaccines failed after a 6–6 vote, with the chair’s tie-breaking decision defeating the measure.
Implications and concerns
Experts and observers raised several concerns about the process and potential effects of the changes:
– Procedural gaps: Working groups typically provide months of clinical and economic analysis before ACIP votes; attendees said that level of preparation appeared to be missing for some motions, raising questions about compliance with ACIP’s charter, which requires consideration of economic evaluations.
– Public confidence: Moving policy proposals without robust supporting data or by tabling key votes could erode public trust in long-standing vaccine recommendations.
– Access and logistics: Shifting COVID-19 shots to shared decision-making may create confusion for patients, clinicians and pharmacists about who should be vaccinated in retail settings and what documentation is needed; pharmacies might limit availability to avoid operational or legal risk.
– Insurance and uptake: Although many insurers say they will continue covering COVID-19 vaccines at least through 2026, weaker recommendations can lead to reduced coverage over time and lower vaccination rates if costs begin to fall on patients.
– Political influence: Critics said the panel’s shifts reflect broader vaccine skepticism within the current administration and warned that modest policy changes could signal further, uncertain shifts in federal guidance.
Voices from the field
Vaccine experts expressed frustration and concern. William Schaffner, MD (Vanderbilt), described the proceedings as ‘‘disappointing and very concerning’’ given the robust evidence supporting vaccine safety and effectiveness. Charles Stoecker, PhD (Tulane), pointed to the lack of expected economic analyses and preparation. Jake Scott, MD (Stanford), said the panel appeared to ‘‘try to solve a problem that didn’t exist’’ with respect to MMRV and warned that abrupt changes to long-standing policies leave clinicians unsure about what may come next. Multiple experts emphasized that infectious diseases cross jurisdictions, and inconsistent guidance risks creating gaps in population immunity.
Bottom line
ACIP’s recent votes make modest but meaningful adjustments: removing the MMRV recommendation for children under 4, indefinitely tabling a proposal to delay the birth hepatitis B vaccine, and narrowing routine COVID-19 vaccination to prioritize older adults while moving most other age groups to shared clinical decision-making. While immediate effects for most Americans are likely limited, public-health specialists warn these actions could complicate vaccine delivery, reduce confidence in established recommendations, and foreshadow larger policy shifts.
